Anti-Androgen Therapy in Polyendocrine Metabolic Ovary Syndrome (PMOS, Formerly PCOS): Efficacy, Safety, and Phenotype-Oriented Clinical Decision-Making
July 2026
in “
Journal of Ovarian Research
”
anti-androgen therapy polyendocrine metabolic ovarian syndrome PMOS polycystic ovary syndrome PCOS hyperandrogenism combined oral contraceptives spironolactone cyproterone acetate finasteride insulin sensitizers metformin cardiovascular safety predictive biomarkers birth control pills Aldactone Androcur Propecia Glucophage
TLDR Anti-androgen therapy is effective and safe for managing PMOS, with a focus on personalized treatment.
This review discusses the role of anti-androgen therapy in managing polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome (PCOS). It highlights the importance of addressing hyperandrogenism, which contributes to reproductive, metabolic, and psychological issues in affected women. The review evaluates the efficacy and safety of various anti-androgen agents, such as combined oral contraceptives, spironolactone, cyproterone acetate, and finasteride, alongside emerging therapies. It emphasizes integrated management strategies, including pharmacotherapy, lifestyle changes, and insulin sensitizers like metformin. Special considerations are given to adolescents, women planning pregnancy, and those with obesity. The review also addresses controversies regarding cardiovascular safety, treatment duration, and the need for predictive biomarkers, proposing a phenotype-guided framework for clinical management.
